Our previous study detected intratumoral heterogeneity in advance stage of lung cancer by surface marker analysis, immunohistochemistry (CD44, ALDH, cMET, MDRI) and FACS (CD44, ALDH, cMET, CD166, MDR-1, uPAR) [5]. This evidence concerns the gene CD44 and lung cancer.